The economic burden of inpatient paediatric care in Kenya: Household and provider costs for treatment of pneumonia, malaria and meningitis

被引：41

作者：

Ayieko P. ^{[1
]}

Akumu A.O. ^{[1
]}

Griffiths U.K. ^{[2
]}

English M. ^{[1
,3
]}

机构：

[1] Kenya Medical Research Institute, Wellcome Trust Research Programme, Nairobi

[2] Health Policy Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT, Keppel Street

[3] Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Headington, Oxford

来源：

Cost Effectiveness and Resource Allocation | / 7卷 / 1期

基金：

英国惠康基金;

关键词：

Malaria; Meningitis; District Hospital; National Hospital; Occupancy Rate;

D O I：

10.1186/1478-7547-7-3

中图分类号：

学科分类号：

摘要：

Background: Knowledge of treatment cost is essential in assessing cost effectiveness in healthcare. Evidence of the potential impact of implementing available interventions against childhood illnesses in developing countries challenges us to define the costs of treating these diseases. The purpose of this study is to describe the total costs associated with treatment of pneumonia, malaria and meningitis in children less than five years in seven Kenyan hospitals. Methods: Patient resource use data were obtained from largely prospective evaluation of medical records and household expenditure during illness was collected from interviews with caretakers. The estimates for costs per bed day were based on published data. A sensitivity analysis was conducted using WHO-CHOICE values for costs per bed day. Results: Treatment costs for 572 children (pneumonia = 205, malaria = 211, meningitis = 102 and mixed diagnoses = 54) and household expenditure for 390 households were analysed. From the provider perspective the mean cost per admission at the national hospital was US $95.58 for malaria, US $177.14 for pneumonia and US $284.64 for meningitis. In the public regional or district hospitals the mean cost per child treated ranged from US $47.19 to US $81.84 for malaria and US $54.06 to US $99.26 for pneumonia. The corresponding treatment costs in the mission hospitals were between US $43.23 to US $88.18 for malaria and US $ 43.36 to US $142.22 for pneumonia. Meningitis was treated for US $ 189.41 at the regional hospital and US $ 201.59 at one mission hospital. The total treatment cost estimates were sensitive to changes in the source of bed day costs. The median treatment related household payments within quintiles defined by total household expenditure differed by type of facility visited. Public hospitals recovered up to 40% of provider costs through user charges while mission facilities recovered 44% to 100% of costs. Conclusion: Treatments cost for inpatient malaria, pneumonia and meningitis vary by facility type, with mission and tertiary referral facilities being more expensive compared to primary referral. Households of sick children contribute significantly towards provider cost through payment of user fees. These findings could be used in cost effectiveness analysis of health interventions. © 2009 Ayieko et al; licensee BioMed Central Ltd.

引用

共 25 条

[1]

Millenium Development Goals in Kenya. Needs and Costs

[2]

Tracking Progressin Maternal, Newborn & Child Survival: The 2008 Report

[3]

Health Management Information Systems. Report for the 1996 to 1999 Period 2001, (2001)

[4]

Jones G., Steketee R.W., Black R.E., Bhutta Z.A., Morris S.S., How many child deaths can we prevent this year?, Lancet, 362, pp. 65-71, (2003)

[5]

English M., Esamai F., Wasunna A., Were F., Ogutu B., Wamae A., Snow R.W., Peshu N., Assessment of inpatient paediatric care in first referral level hospitals in 13 districts in Kenya, Lancet, 363, pp. 1948-1953, (2004)

[6]

Nolan T., Angos P., Cunha A.J., Muhe L., Qazi S., Simoes E.A., Tamburlini G., Weber M., Pierce N.F., Quality of hospital care for seriously ill children in less-developed countries, Lancet, 357, pp. 106-110, (2001)

[7]

Snow R.W., Mung'ala V.O., Foster D., Marsh K., The role of the district hospital in child survival at the Kenyan Coast, Afr J Health Sci, 1, pp. 71-75, (1994)

[8]

(2003)

[9]

Cutts F., Zaman S., Enwere G., Jaffar S., Levine O., Okoko J., Oluwalana C., Vaughan A., Obaro S., Leach A., Et al., Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: Randomised, double-blind, placebo-controlled trial, Lancet, 365, pp. 1139-1146, (2005)

[10]

Scott J., Brooks W., Peiris J., Holtzman D., Mulholland E., Pneumonia research to reduce childhood mortality in the developing world, J Clin Invest, 118, pp. 1291-1300, (2008)

← 1 2 3 →